iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease

iBio Inc IBIO received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company's lead COVID-19 vaccine program. 

• In light of the feedback received, the Company is moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid (N) protein. 
• It plans to file an IND application before the end of calendar 2022.
• The Company previously reported completing extensive preclinical studies and identifying an antigen-adjuvant pairing with a favorable Th1 skew. 
• The cytokine response observed with this pairing indicated a primary immune response, differentiation of mature T cells, and reactivation of memory T-cells.
• In September 2021, iBio submitted a pre-IND package for IBIO-202 to the FDA. 
• In November 2021, the Company entered a collaboration agreement with a provider of microarray patch systems to evaluate the feasibility of intradermal delivery of a COVID-19 vaccine antigen. 
• Price Action: IBIO shares are down 1.29% at $0.47 during the market session on the last check Wednesday.